# US 2022/0017639 A1 · Methods for increasing thermogenic adipocytes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0017639 A1
- Document ID: US20220017639A1
- Status: Published application
- Kind: A1
- Application number: 17/186,072
- Filed: 2021-02-26
- Published: 2022-01-20
- Earliest claimed: 2009-06-08
- Assignees: Acceleron Pharma Inc.
- Applicants: Acceleron Pharma Inc.
- Inventors: John Knopf; Jasbir Seehra; Ravindra Kumar
- Web page: https://patentgrep.com/patent/US20220017639A1

## CPC

- A61K 38/179: {for growth factors; for growth regulators}
- C07K 16/40: against enzymes
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/1796: {for hormones (for neuromediators A61K38/1787)}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C07K 14/71: for growth factors; for growth regulators
- C12N 5/0653: {Adipocytes; Adipose tissue}
- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A method for increasing thermogenic adipocytes in a patient in need thereof, the method comprising administering an effective amount of a polypeptide comprising an amino acid sequence that is at least 95% identical to the sequence of amino acids 29-109 of SEQ ID NO: 2, wherein administration of the polypeptide increases SIRT-1 and/or PGC-1α mRNA levels in adipocytes of the treated patient.

### Claim 12 (depends on 11)

The method of claim 11, wherein the polypeptide is a fusion protein comprising a portion heterologous to ActRIIB.

### Claim 13 (depends on 12)

The method of claim 12, wherein the polypeptide is fused to a constant domain of an immunoglobulin.

### Claim 14 (depends on 12)

The method of claim 12, wherein the polypeptide is fused to an Fc portion of an immunoglobulin.

### Claim 15 (depends on 14)

The method of claim 14, wherein the immunoglobulin is a human IgG1.

### Claim 16 (depends on 11)

The method of claim 11, wherein the polypeptide is a dimer.

### Claim 17 (depends on 11)

The method of claim 11, wherein the polypeptide comprises the sequence of SEQ ID NO: 5.

### Claim 18 (depends on 11)

The method of claim 11, wherein the polypeptide comprises an amino acid sequence that is at least 97% identical to the sequence of amino acids 29-109 of SEQ ID NO: 2.

### Claim 19 (depends on 11)

The method of claim 11, wherein the polypeptide comprises an amino acid sequence that is at least 90% identical to the sequence of amino acids 25-131 of SEQ ID NO: 2.

### Claim 20 (depends on 19)

The method of claim 19, wherein the polypeptide comprises an amino acid sequence that is at least 95% identical to the sequence of amino acids 25-131 of SEQ ID NO: 2.

### Claim 21 (depends on 20)

The method of claim 20, wherein the polypeptide comprises an amino acid sequence that is at least 97% identical to the sequence of amino acids 25-131 of SEQ ID NO: 2.

### Claim 22 (depends on 11)

The method of claim 11, wherein administration of the polypeptide increases SIRT-1 mRNA levels in adipocytes of the treated patient.

### Claim 23 (depends on 11)

The method of claim 11, wherein administration of the polypeptide increases PGC-1α mRNA levels in adipocytes of the treated patient.

### Claim 24 (depends on 11)

The method of claim 11, wherein administration of the polypeptide increases SIRT-1 and PGC-1α mRNA levels in adipocytes of the treated patient.

### Claim 25 (depends on 11)

The method of claim 11, wherein administration of the compound promotes uncoupling protein-1 (UCP-1) expression in adipocytes of the treated patient.

### Claim 26 (depends on 11)

The method of claim 11, wherein the polypeptide comprises the sequence of SEQ ID NO: 6.
